Effect of valsartant on ventricular remodeling in patients with myocardial infarction after percutaneous coronary intervention

Objective:To observe impact of valsartant on ventricular remodeling for MI patients after PCI.Method:Chose 58 patients with myocardial infarction and treated with PCI therapy. 28 patients took valsartant (80 mg/d) after the operations, and the others not. Both groups took 99 TCmMIBI myocardial perfusion imaging test assessing left ventricular size and function at 3 days before 3 months and 6 months after the operations regarding left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), left ventricular ejection fraction (LVEF), etc, Clinical follow-up was obtained.Result:Before PCI therapy and during 3 months of follow-up after the therapy, there were not significant difference between the two groups in LVEDV, LVESV and LVEF. However, significant changes in LVEDV[(102.6±25.6)mL vs (117.2±28.5)mL P=0.045]and LVESV [(53.1±20.6)mL vs (66.4±28.7)mL P=0.049] were observed within the two groups at 6 months of the follow-up,and the LVEF of valsartant group increased dramatically than the normally treated group [(56.1±9.6)% vs (47.4±13.2)% P=0.006]. During a follow-up duration of 13 months, combined clinical events rate (myocardial infarction again, heart failure, angina pectoris, stroke, death, revascularization and so on), favors a policy of valsartant group(24.0% vs 46.7% P=0.04).Conclusion:Patients with myocardial infaction should take the specific antagonist of AT1 receptor valsartant on time just after percutaneous coronary intervention therapy. It can keep away from ventricular remodeling more efficiently and protect left ventricular function. Furthermore, it can promate patients' recovery and improve living rate.